Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs TKO Group Holdings Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.43 (market cap $6.04B), while TKO Group Holdings Inc trades at $181.63 (market cap $13.28B). The key difference: TKO Group Holdings Inc is far larger — about 2.2× Iovance Biotherapeutics Inc. Common Stock's market cap, and TKO Group Holdings Inc pays a 1.74% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and TKO Group Holdings Inc for 30 Days on average.
| IOVA | TKO | |
|---|---|---|
Market Cap | $6.04B | $13.28B |
Volume | 14,805,993 | 857,653 |
Sector | Health | Media |
52-Week High | $14.82 | $224.96 |
52-Week Low | $1.81 | $175.58 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $5.97B | $17.64B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TKO trades at $178.64, up 1.24% on the day but near recent lows, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates but raising full-year guidance. Revenue growth is solid, with 2026 projected at $5.3B, though net margins remain thin at 4.33%. A quarterly dividend of $0.79 was declared for payment in September 2026.
The stock presents a contrast between strong analyst bullishness (89% buy rating, $227 consensus target) and current technical weakness. Upside hinges on execution of media rights monetization and live event growth, while risks include competitive pressures and margin sustainability. The valuation at a P/E of 63.73 demands high future earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
